Retrospective cohort study identifies lipid accumulation product as a significant mortality predictor in T2DM-HFrEF, suggesting a critical monitoring tool.
To evaluate lipid accumulation product (LAP) as a predictor of all-cause mortality in type 2 diabetes mellitus (T2DM) patients with heart failure with reduced ejection fraction (HFrEF). Among 926 T2DM-HFrEF patients followed for 29.9 months (median), high LAP independently predicted increased mortality risk (adjusted HR: 3.102, 95% CI 2.142-4.491; P < 0.001). LAP exhibited a nonlinear association with mortality (P for Nonlinear < 0.001) and demonstrated moderate predictive accuracy (AUC = 0.643, 95% CI 0.602-0.684).
No takes yet. Share an insight, caveat, or question.
Wang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: